The convergence of cell biology and genetic engineering is creating fundamental new ways to impact disease. Capitalizing on these technological breakthroughs, BlueRock are advancing novel cell+gene platform to develop, manufacture, and deliver an entirely new generation of authentic and engineered cell therapies, across neurology, cardiology and immunology. Lead program is a first-in-class cellular therapy in development for the treatment of Parkinson’s disease.
Emile Nuwaysir, Ph.D. is President and CEO of BlueRock. He joined BlueRock in Feb 2017, bringing nearly 20 years of experience in creating and guiding innovative life science companies from startup stage to fully integrated biotech companies. He was the President of a regenerative medicine division of Fujifilm, President of Opsis Therapeutics, CTO at Roche NimbleGen, VP of Business Development at NimbleGen Systems. Emile currently also holds positions of vice-chairman for the Alliance for Regenerative Medicine, and founder and vice-chairman of Invenra, Inc. He completed his Ph.D. from the University of Wisconsin-Madison and postdoctoral fellowships at the National Institutes of Health and UNC-Chapel Hill.